Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD0004J08 in adults with asymptomatic to moderately severe COVID-19
2020-005532-29Phase 2Completed
- Sponsor
- Toscana Life Sciences Sviluppo
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MAD0004J08 with Placebo (2 arms). Primary endpoint: Safety endpoints (primary). Started Apr 2021; status: completed.
02
Drugs
MAbCo19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005532-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005532-29.